688217 睿昂基因
已收盘 09-14 15:00:00
资讯
新帖
简况
每周股票复盘:睿昂基因(688217)Q2净利下滑3792.06%
证券之星 · 08-30
每周股票复盘:睿昂基因(688217)Q2净利下滑3792.06%
睿昂基因(688217)披露2026年半年度报告,8月28日股价下跌0.4%
证券之星 · 08-28
睿昂基因(688217)披露2026年半年度报告,8月28日股价下跌0.4%
图解睿昂基因中报:第二季度单季净利润同比下降3792.06%
证券之星 · 08-27
图解睿昂基因中报:第二季度单季净利润同比下降3792.06%
睿昂基因2026年半年报:核心产品入院增长,净利润由盈转亏
蓝鲸财经 · 08-27
睿昂基因2026年半年报:核心产品入院增长,净利润由盈转亏
每周股票复盘:睿昂基因(688217)股东减持5.69万股,持股比例降至10%
证券之星 · 08-16
每周股票复盘:睿昂基因(688217)股东减持5.69万股,持股比例降至10%
股市必读:睿昂基因新发布《睿昂基因简式权益变动报告书》
证券之星 · 08-13
股市必读:睿昂基因新发布《睿昂基因简式权益变动报告书》
睿昂基因(688217)披露持股5%以上股东权益变动触及5%整数倍的提示性公告,8月11日股价下跌1.95%
证券之星 · 08-11
睿昂基因(688217)披露持股5%以上股东权益变动触及5%整数倍的提示性公告,8月11日股价下跌1.95%
8月11日睿昂基因发布公告,股东减持5.69万股
证券之星 · 08-11
8月11日睿昂基因发布公告,股东减持5.69万股
每周股票复盘:睿昂基因(688217)股东会通过董事薪酬制度议案
证券之星 · 07-05
每周股票复盘:睿昂基因(688217)股东会通过董事薪酬制度议案
睿昂基因(688217)披露关于制定《董事、高级管理人员薪酬管理制度》的议案获通过,6月30日股价上涨1.62%
证券之星 · 06-30
睿昂基因(688217)披露关于制定《董事、高级管理人员薪酬管理制度》的议案获通过,6月30日股价上涨1.62%
每周股票复盘:睿昂基因(688217)股东拟减持不超3%股份
证券之星 · 06-28
每周股票复盘:睿昂基因(688217)股东拟减持不超3%股份
睿昂基因(688217)披露2025年年度股东会决议公告,6月24日股价下跌5.28%
证券之星 · 06-24
睿昂基因(688217)披露2025年年度股东会决议公告,6月24日股价下跌5.28%
睿昂基因(688217)披露关于制定《董事、高级管理人员薪酬管理制度》的议案,6月23日股价上涨0.58%
证券之星 · 06-23
睿昂基因(688217)披露关于制定《董事、高级管理人员薪酬管理制度》的议案,6月23日股价上涨0.58%
睿昂基因(688217.SH):浙江大健康拟减持不超3%股份
智通财经 · 06-22
睿昂基因(688217.SH):浙江大健康拟减持不超3%股份
股市必读:睿昂基因(688217)6月18日披露最新机构调研信息
证券之星 · 06-22
股市必读:睿昂基因(688217)6月18日披露最新机构调研信息
睿昂基因(688217)披露2025年年度股东会会议资料,6月16日股价下跌0.39%
证券之星 · 06-16
睿昂基因(688217)披露2025年年度股东会会议资料,6月16日股价下跌0.39%
每周股票复盘:睿昂基因(688217)2025年营收1.77亿同比下滑26.84%
证券之星 · 05-31
每周股票复盘:睿昂基因(688217)2025年营收1.77亿同比下滑26.84%
股市必读:新发布《上海市锦天城律师事务所关于上海睿昂基因科技股份有限公司2025年年度报告的信息披露监管问询函有关事项的法律意见书》
中金财经 · 05-27
股市必读:新发布《上海市锦天城律师事务所关于上海睿昂基因科技股份有限公司2025年年度报告的信息披露监管问询函有关事项的法律意见书》
睿昂基因(688217)披露关于2025年年度报告信息披露监管问询函有关事项的法律意见书,5月26日股价下跌2.36%
证券之星 · 05-26
睿昂基因(688217)披露关于2025年年度报告信息披露监管问询函有关事项的法律意见书,5月26日股价下跌2.36%
睿昂基因(688217)披露关于2025年年度报告的信息披露监管问询函回复公告,5月25日股价下跌3.27%
证券之星 · 05-25
睿昂基因(688217)披露关于2025年年度报告的信息披露监管问询函回复公告,5月25日股价下跌3.27%
公司概况
公司名称:
上海睿昂基因科技股份有限公司
所属行业:
医药制造业
上市日期:
2021-05-17
主营业务:
上海睿昂基因科技股份有限公司的主营业务是体外诊断产品的研发、生产、销售及科研、检测服务。公司的主要产品是体外诊断试剂盒、科研服务、医学检测服务、体外诊断仪器。公司先后获得了“上海市专精特新企业”、“奉贤区科技小巨人企业”等荣誉称号,并多次承担由国家科技部、上海市科学技术委员会、上海张江高新技术产业开发区管理委员会等部门主导的多个重大科研项目。
发行价格:
18.42
{"stockData":{"symbol":"688217","market":"SH","secType":"STK","nameCN":"睿昂基因","latestPrice":23.61,"timestamp":1789369200000,"preClose":23.18,"halted":0,"volume":796685,"delay":0,"changeRate":0.0186,"floatShares":55855900,"shares":55855900,"eps":-1.1865,"marketStatus":"已收盘","change":0.43,"latestTime":"09-14 15:00:00","open":23.14,"high":23.87,"low":22.75,"amount":18691100,"amplitude":0.0483,"askPrice":23.62,"askSize":3,"bidPrice":23.61,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.1865,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789435800000},"marketStatusCode":5,"adr":0,"adjPreClose":23.18,"symbolType":"stock_kcb","openAndCloseTimeList":[[1789349400000,1789356600000],[1789362000000,1789369200000]],"highLimit":25.5,"lowLimit":20.86,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":55855896,"isCdr":false,"pbRate":1.58,"roa":"--","roe":"--","epsLYR":-0.91,"committee":-0.320755,"marketValue":1319000000,"turnoverRate":0.0143,"status":0,"afterMarket":{"amount":0,"volume":0,"close":23.61,"buyVolume":0,"sellVolume":900,"time":1789371237746,"indexStatus":"已收盘 09-14 15:30:00","preClose":23.18},"floatMarketCap":1319000000},"requestUrl":"/m/hq/s/688217/wiki","defaultTab":"wiki","newsList":[{"id":"2663045870","title":"每周股票复盘:睿昂基因(688217)Q2净利下滑3792.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663045870","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663045870?lang=zh_cn&edition=full","pubTime":"2026-08-30 09:04","pubTimestamp":1788051852,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘,睿昂基因报收于24.76元,较上周的24.77元下跌0.04%。本周,睿昂基因8月28日盘中最高价报25.68元。公司公告汇总上海睿昂基因科技股份有限公司2026年半年度报告摘要显示,报告期末公司总资产为861,967,948.88元,较上年度末下降2.65%;归属于上市公司股东的净资产为832,534,263.08元,较上年度末下降1.46%。公司对截至2026年6月30日的信用及资产进行减值测试,2026年半年度合计计提信用及资产减值准备12,257,156.56元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000004506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688217","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662067304","title":"睿昂基因(688217)披露2026年半年度报告,8月28日股价下跌0.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662067304","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662067304?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:22","pubTimestamp":1787916136,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘,睿昂基因报收于24.76元,较前一交易日下跌0.4%,最新总市值为13.83亿元。公司于近日披露《2026年半年度报告》。本报告期实现营业收入79,836,487.02元,同比下降20.42%;利润总额为-10,359,149.57元;归属于上市公司股东的净利润为-12,340,876.58元,同比下降447.21%;归属于上市公司股东的扣除非经常性损益的净利润为-18,514,751.02元。经营活动产生的现金流量净额为12,705,351.67元,同比下降27.34%。研发投入占营业收入的比例为24.28%,较上年同期减少7.27个百分点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800045090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688217","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662709729","title":"图解睿昂基因中报:第二季度单季净利润同比下降3792.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662709729","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662709729?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:04","pubTimestamp":1787828659,"startTime":"0","endTime":"0","summary":"证券之星消息,睿昂基因2026年中报显示,上半年度公司主营收入7983.65万元,同比下降20.42%;归母净利润-1234.09万元,同比下降447.21%;扣非净利润-1851.48万元,同比下降554.83%;其中2026年第二季度,公司单季度主营收入4397.24万元,同比下降12.07%;单季度归母净利润-735.77万元,同比下降3792.06%;单季度扣非净利润-1306.51万元,同比下降510.65%;负债率3.88%,投资收益586.79万元,财务费用159.72万元,毛利率77.41%。财报数据概要请见下图:本文数据来源于睿昂基因2026年中报,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700045216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688217"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662708181","title":"睿昂基因2026年半年报:核心产品入院增长,净利润由盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2662708181","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662708181?lang=zh_cn&edition=full","pubTime":"2026-08-27 17:55","pubTimestamp":1787824519,"startTime":"0","endTime":"0","summary":"蓝鲸新闻8月27日讯,8月27日,睿昂基因 公布2026年中报,公司聚焦肿瘤精准检测领域,受制于体外诊断行业竞争加剧及监管趋严影响,报告期业绩承压,营收与利润双双下滑;同时,因子公司业绩不及预期计提商誉减值及冲销递延所得税资产,进一步拖累净利润表现,但核心产品入院数量仍保持增长。财报数据显示,报告期公司实现营业收入7983.65万元,同比下降20.42%;归母净利润-1234.09万元,同比由盈转亏;扣非归母净利润-1851.48万元,亏损幅度扩大。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787821202301292962","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["688217"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659176305","title":"每周股票复盘:睿昂基因(688217)股东减持5.69万股,持股比例降至10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659176305","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659176305?lang=zh_cn&edition=full","pubTime":"2026-08-16 02:52","pubTimestamp":1786819931,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘,睿昂基因报收于24.7元,较上周的23.19元上涨6.51%。本周关注点股本股东变化:股东浙江大健康基金减持5.69万股,持股比例由11.25%降至10.00%。股本股东变化股东增减持8月11日睿昂基因发布公告,股东浙江大健康产业股权投资基金于2026年7月16日至2026年8月10日间合计减持5.69万股,占公司目前总股本的0.1019%,变动期间该股股价上涨8.23%,截止8月10日收盘报24.6元。本次权益变动后持有睿昂基因5,585,464股,均为无限售流通股,无质押、冻结等情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688217","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659902360","title":"股市必读:睿昂基因新发布《睿昂基因简式权益变动报告书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659902360","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659902360?lang=zh_cn&edition=full","pubTime":"2026-08-13 02:30","pubTimestamp":1786559434,"startTime":"0","endTime":"0","summary":"睿昂基因关于持股5%以上股东权益变动触及5%整数倍的提示性公告浙江大健康产业股权投资基金持股比例由11.25%降至10.00%,权益变动触及5%整数倍;本次变动未触发强制要约收购义务,不导致实际控制人变化;相关信息披露义务人已披露简式权益变动报告书;减持计划尚未实施完毕,公司将继续履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300001628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688217"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658919580","title":"睿昂基因(688217)披露持股5%以上股东权益变动触及5%整数倍的提示性公告,8月11日股价下跌1.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658919580","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658919580?lang=zh_cn&edition=full","pubTime":"2026-08-11 22:27","pubTimestamp":1786458446,"startTime":"0","endTime":"0","summary":"截至2026年8月11日收盘,睿昂基因报收于24.12元,较前一交易日下跌1.95%,最新总市值为13.47亿元。近日,睿昂基因发布《关于持股5%以上股东权益变动触及5%整数倍的提示性公告》。公告显示,公司持股5%以上股东浙江大健康产业股权投资基金通过集中竞价方式减持股份,持股比例由11.25%降至10.00%,权益变动触及5%整数倍。本次变动未触发强制要约收购义务,不导致实际控制人变化。相关信息披露义务人已披露简式权益变动报告书。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100038443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688217","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658999287","title":"8月11日睿昂基因发布公告,股东减持5.69万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658999287","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658999287?lang=zh_cn&edition=full","pubTime":"2026-08-11 18:01","pubTimestamp":1786442475,"startTime":"0","endTime":"0","summary":"证券之星消息,8月11日睿昂基因发布公告《睿昂基因:睿昂基因关于持股5%以上股东权益变动触及5%整数倍的提示性公告》,其股东浙江大健康产业股权投资基金(有限合伙)于2026年7月16日至2026年8月10日间合计减持5.69万股,占公司目前总股本的0.1019%,变动期间该股股价上涨8.23%,截止8月10日收盘报24.6元。股东增减持详情见下表:根据睿昂基因2026年一季报公布的十大股东详情如下:本文数据来源于睿昂基因公告,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100031072.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688217"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649692784","title":"每周股票复盘:睿昂基因(688217)股东会通过董事薪酬制度议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2649692784","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649692784?lang=zh_cn&edition=full","pubTime":"2026-07-05 04:29","pubTimestamp":1783196949,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘,睿昂基因报收于22.46元,较上周的20.34元上涨10.42%。本周,睿昂基因7月2日盘中最高价报23.0元。会议审议通过了《关于制定<董事、高级管理人员薪酬管理制度>的议案》,所有议案均获通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500001607.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688217","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647433537","title":"睿昂基因(688217)披露关于制定《董事、高级管理人员薪酬管理制度》的议案获通过,6月30日股价上涨1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647433537","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647433537?lang=zh_cn&edition=full","pubTime":"2026-06-30 18:27","pubTimestamp":1782815238,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘,睿昂基因报收于20.66元,较前一交易日上涨1.62%,最新总市值为11.54亿元。该股当日开盘19.88元,最高20.84元,最低19.88元,成交额达2308万元,换手率为2.03%。近日,睿昂基因发布2026年第一次临时股东会决议公告。出席会议股东共19人,代表有表决权股份8,154,613股,占公司总表决权股份的14.7765%。会议审议通过了《关于制定<董事、高级管理人员薪酬管理制度>的议案》,所有议案均获通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000036304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688217"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646163903","title":"每周股票复盘:睿昂基因(688217)股东拟减持不超3%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2646163903","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646163903?lang=zh_cn&edition=full","pubTime":"2026-06-28 04:11","pubTimestamp":1782591070,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘,睿昂基因报收于20.34元,较上周的22.33元下跌8.91%。本周,睿昂基因6月23日盘中最高价报23.14元。公司公告汇总浙江大健康产业股权投资基金持有睿昂基因5,642,401股,占总股本的10.10%,计划于2026年7月14日至10月13日期间,通过集中竞价和大宗交易方式减持不超过1,675,675股,即不超过公司总股本的3%。本次减持不会导致公司控制权变更。出席会议股东及代理人共17人,代表有表决权股份8,150,526股,占公司总股本的14.7691%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800001391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688217"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645811996","title":"睿昂基因(688217)披露2025年年度股东会决议公告,6月24日股价下跌5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645811996","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645811996?lang=zh_cn&edition=full","pubTime":"2026-06-24 22:47","pubTimestamp":1782312433,"startTime":"0","endTime":"0","summary":"截至2026年6月24日收盘,睿昂基因报收于21.34元,较前一交易日下跌5.28%,最新总市值为11.92亿元。该股当日开盘22.64元,最高22.95元,最低21.21元,成交额达2333.6万元,换手率为1.91%。近日,睿昂基因发布《2025年年度股东会决议公告》。公告显示,公司于2026年6月24日召开2025年年度股东会,会议由董事会召集,董事长高尚先主持,采用现场与网络投票结合方式召开。出席会议股东及代理人共17人,代表有表决权股份8,150,526股,占公司总表决权股份的14.7691%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400044299.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688217"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645887964","title":"睿昂基因(688217)披露关于制定《董事、高级管理人员薪酬管理制度》的议案,6月23日股价上涨0.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645887964","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645887964?lang=zh_cn&edition=full","pubTime":"2026-06-23 17:53","pubTimestamp":1782208421,"startTime":"0","endTime":"0","summary":"截至2026年6月23日收盘,睿昂基因报收于22.53元,较前一交易日上涨0.58%,最新总市值为12.58亿元。该股当日开盘21.94元,最高23.14元,最低21.89元,成交额达2112.04万元,换手率为1.67%。近日,睿昂基因发布2026年第一次临时股东会会议资料公告。公司将于2026年6月29日召开2026年第一次临时股东会,审议《关于制定<董事、高级管理人员薪酬管理制度>的议案》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300031339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688217","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645267540","title":"睿昂基因(688217.SH):浙江大健康拟减持不超3%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2645267540","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645267540?lang=zh_cn&edition=full","pubTime":"2026-06-22 18:44","pubTimestamp":1782125044,"startTime":"0","endTime":"0","summary":"智通财经APP讯,睿昂基因(688217.SH)发布公告,公司股东浙江大健康产业股权投资基金(有限合伙)(简称“浙江大健康”)计划自公告披露之日起15个交易日后的3个月内通过集中竞价、大宗交易方式择机减持公司股份,减持数量合计不超过公司总股本的3%,即不超过167.57万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688217","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645016774","title":"股市必读:睿昂基因(688217)6月18日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2645016774","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645016774?lang=zh_cn&edition=full","pubTime":"2026-06-22 05:15","pubTimestamp":1782076514,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,睿昂基因报收于22.33元,上涨0.77%,换手率1.55%,成交量8639.0手,成交额1914.59万元。机构调研要点6月18日业绩说明会,网上关于原实控人诉讼进展:案件因复杂性及保密要求存在延期可能,目前无新进展,公司将依规及时公告。关于自产试剂收入:2025年自产试剂实现收入1.52亿元,占主营业务收入的85.84%。关于核心产品收入:2025年白血病分子检测试剂盒收入1.08亿元,淋巴瘤重排检测试剂盒产品及服务收入2,969.43万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200001773.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688217"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643061759","title":"睿昂基因(688217)披露2025年年度股东会会议资料,6月16日股价下跌0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643061759","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643061759?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:01","pubTimestamp":1781607660,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘,睿昂基因报收于22.87元,较前一交易日下跌0.39%,最新总市值为12.77亿元。该股当日开盘22.98元,最高23.18元,最低22.22元,成交额达1863.34万元,换手率为1.47%。近日,睿昂基因发布《2025年年度股东会会议资料》。公告显示,公司定于2026年6月24日召开2025年年度股东会,会议将审议2025年度董事会工作报告、独立董事述职报告、2025年度利润分配预案、2026年度董事薪酬方案及修订公司部分内部管理制度等议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600036826.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688217","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639604723","title":"每周股票复盘:睿昂基因(688217)2025年营收1.77亿同比下滑26.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639604723","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2639604723?lang=zh_cn&edition=full","pubTime":"2026-05-31 04:10","pubTimestamp":1780171819,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘,睿昂基因报收于25.16元,较上周的28.48元下跌11.66%。本周,睿昂基因5月25日盘中最高价报28.98元。本周关注点来自业绩披露要点:睿昂基因2025年营收1.77亿元,同比下滑26.84%,归母净利润亏损5037.71万元。公司2025年营收1.77亿元,同比下滑26.84%,归母净利润亏损5037.71万元,主要因核心试剂产品量价双跌、市场竞争加剧、行业政策调整所致。上海市锦天城律师事务所就睿昂基因2025年年度报告信息披露监管问询函相关事项出具法律意见书。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100001281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688217"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638529104","title":"股市必读:新发布《上海市锦天城律师事务所关于上海睿昂基因科技股份有限公司2025年年度报告的信息披露监管问询函有关事项的法律意见书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2638529104","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638529104?lang=zh_cn&edition=full","pubTime":"2026-05-27 07:57","pubTimestamp":1779839865,"startTime":"0","endTime":"0","summary":"上海市锦天城律师事务所关于上海睿昂基因科技股份有限公司2025年年度报告的信息披露监管问询函有关事项的法律意见书上海市锦天城律师事务所就上海睿昂基因科技股份有限公司2025年年度报告信息披露监管问询函相关事项出具法律意见书。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260527/32255949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688217","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638453315","title":"睿昂基因(688217)披露关于2025年年度报告信息披露监管问询函有关事项的法律意见书,5月26日股价下跌2.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638453315","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638453315?lang=zh_cn&edition=full","pubTime":"2026-05-26 22:58","pubTimestamp":1779807496,"startTime":"0","endTime":"0","summary":"截至2026年5月26日收盘,睿昂基因报收于26.9元,较前一交易日下跌2.36%,最新总市值为15.03亿元。该股当日开盘27.55元,最高27.79元,最低26.3元,成交额达2507.46万元,换手率为1.66%。公告显示,上海市锦天城律师事务所就公司2025年年度报告信息披露监管问询函相关事项出具法律意见书。公司及子公司未被限制经营范围或吊销资质。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600041612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688217"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638556591","title":"睿昂基因(688217)披露关于2025年年度报告的信息披露监管问询函回复公告,5月25日股价下跌3.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638556591","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638556591?lang=zh_cn&edition=full","pubTime":"2026-05-25 22:46","pubTimestamp":1779720376,"startTime":"0","endTime":"0","summary":"截至2026年5月25日收盘,睿昂基因报收于27.55元,较前一交易日下跌3.27%,最新总市值为15.39亿元。该股当日开盘28.63元,最高28.98元,最低27.2元,成交额达3351.51万元,换手率为2.15%。近日,睿昂基因发布《关于2025年年度报告的信息披露监管问询函回复公告》。公司2025年营收1.77亿元,同比下滑26.84%,归母净利润亏损5037.71万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500034271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688217","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789399608881,"stockEarnings":[{"period":"1week","weight":-0.0523},{"period":"1month","weight":-0.0386},{"period":"3month","weight":-0.0132},{"period":"6month","weight":-0.2232},{"period":"1year","weight":-0.1982},{"period":"ytd","weight":-0.1203}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":-0.0148},{"period":"3month","weight":-0.0356},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0033},{"period":"ytd","weight":-0.0203}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海睿昂基因科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"4424人(较上一季度减少3.15%)","perCapita":"12625股","listingDate":"2021-05-17","address":"上海市奉贤区金海公路6055号3幢","registeredCapital":"5585万元","survey":" 上海睿昂基因科技股份有限公司的主营业务是体外诊断产品的研发、生产、销售及科研、检测服务。公司的主要产品是体外诊断试剂盒、科研服务、医学检测服务、体外诊断仪器。公司先后获得了“上海市专精特新企业”、“奉贤区科技小巨人企业”等荣誉称号,并多次承担由国家科技部、上海市科学技术委员会、上海张江高新技术产业开发区管理委员会等部门主导的多个重大科研项目。","listedPrice":18.42},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"睿昂基因(688217)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供睿昂基因(688217)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"睿昂基因,688217,睿昂基因股票,睿昂基因股票老虎,睿昂基因股票老虎国际,睿昂基因行情,睿昂基因股票行情,睿昂基因股价,睿昂基因股市,睿昂基因股票价格,睿昂基因股票交易,睿昂基因股票购买,睿昂基因股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"睿昂基因(688217)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供睿昂基因(688217)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}